BCM
EBS icon

Beck Capital Management’s Emergent Biosolutions EBS Stock Holding History

Beck Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,067
Closed -$2.28M – 111
2020
Q3 		$2.28M Buy
+22,067
New +$2.38M 1.29% 35

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Beck Capital Management's EBS Position: Q4 2020 in Review

Beck Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 22,067 shares — an estimated $2.28M sold.

Beck Capital Management first reported a position in EBS in Q3 2020 and held it in 1 quarter. The position peaked at $2.28M in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Beck Capital Management reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
  • Beck Capital Management sold 22,067 Emergent Biosolutions shares in Q4 2020, an estimated $2.28M.
  • Beck Capital Management first reported a position in Emergent Biosolutions in Q3 2020 and held it in 1 quarter.
  • Beck Capital Management's Emergent Biosolutions position peaked at $2.28M in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Beck Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.